Unlocking the potential of epigenetic therapeutics to revolutionize medicine
DURECT harnesses epigenetic regulation to treat acute and chronic organ injury. Our unique approach has the potential to change the course of disease and improve patients’ lives.
Alcohol-Associated Hepatitis (AH)
We are currently conducting a Phase 2b study (AHFIRM) in subjects with Alcohol-Associated Hepatitis (AH) in more than 60 clinical trial sites across the US, EU, UK, and Australia.
Partner with us
We welcome strategic partnerships to advance our collective goal to meaningfully impact patients’ lives and offer better therapeutic options.
Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies.
Nov 28, 2022, 18:46 ET CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs
Nov 02, 2022, 16:05 ET – Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET – AHFIRM trial timeline continues to improve CUPERTINO,
- Argemi J, Latasa MU, Atkinson SR, et al. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nat Commun. 2019;10(1):3126. doi:10.1038/s41467-019-11004-3
- Mazzone R, Zwergel C, Artico M, et al. The emerging role of epigenetics in human autoimmune disorders. Clin Epigenetics. 2019;11(1):34. doi:10.1186/s13148-019-0632-2
- Herman A, Occean JR, Sen P. Epigenetic dysregulation in cardiovascular aging and disease. J Cardiovasc Aging. 2021;1:10. doi:10.20517/jca.2021.16
- Hassanein T, Stein L, Flamm S, et al. Safety and efficacy of DUR-928: A potential new therapy for acute alcoholic hepatitis. Late-breaking oral presentation at AASLD The Liver Meeting®; 2019 November 12.